Aytu BioPharma(AYTU)
DENVER, CODiagnostics
Focus: Aytu BioPharma is a publicly traded specialty pharmaceutical company focused on small-molecule drugs and diagnostics across gastroenterology, infectious diseases, and oncology. The company generates ~$66M in annual revenue with a portfolio of established brands and early-stage pipeline programs.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Aytu BioPharma
AI assessmentNot HiringNo open roles listed right now. Follow Aytu BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Aytu BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
1 in 5yr
KARBINAL ER
Hiring
0 open
Revenue
$66M
FY2026
Key Products
Peak5.7yr
Lead product at peak revenue with 6+ year LOE runway; supports current commercial operations.
Help build intelligence for Aytu BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.